Harmony Biosciences Holdings (HRMY) Payables (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Payables data on file, last reported at $28.6 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 63.81% year-over-year to $28.6 million; the trailing twelve-month figure through Mar 2026 stood at $28.6 million (up 63.81% YoY), and the FY2025 full-year result was $17.7 million, up 28.73% from the prior year.
• Payables grew to $28.6 million in Q1 2026, from $17.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $28.6 million in Q1 2026 to a low of $3.8 million in Q4 2022.
• A 5-year average of $14.4 million and a median of $13.7 million in 2024 frame the typical range for Payables.
• Peak annual rise in Payables reached 368.3% in 2023, while the deepest fall reached 34.93% in 2023.
• Tracing HRMY's Payables over 5 years: stood at $3.8 million in 2022, then jumped by 368.3% to $17.7 million in 2023, then dropped by 22.48% to $13.7 million in 2024, then increased by 28.73% to $17.7 million in 2025, then surged by 61.65% to $28.6 million in 2026.
• Business Quant data shows HRMY's Payables at $28.6 million in Q1 2026, $17.7 million in Q4 2025, and $26.3 million in Q3 2025.